In a dental consultation for a patient with multiple myeloma, what is the most critical information to ask the treating oncologist?

For patients with multiple myeloma, it is crucial to know the chemotherapy medications they are receiving because certain drugs, such as bisphosphonates (e.g., zoledronic acid) or RANKL inhibitors (e.g., denosumab), are commonly used to manage bone complications. These drugs significantly increase the risk of medication-related osteonecrosis of the jaw (MRONJ), which is a serious complication in dental procedures. Other factors to consider: Radiation therapy (option a) is less common in multiple myeloma but may be relevant if used for localized bone lesions. CBC results (option c) are important for assessing immune function and bleeding risk but are secondary to understanding the risk of MRONJ. Renal function (option d) is relevant because multiple myeloma often affects the kidneys, but it does not directly influence dental treatment planning as much as the medication regimen does.